Zobrazeno 1 - 10
of 19
pro vyhledávání: '"Jill Donelan"'
Autor:
Gregory Hather, Ray Liu, Syamala Bandi, Jerome Mettetal, Mark Manfredi, Wen-Chyi Shyu, Jill Donelan, Arijit Chakravarty
Publikováno v:
Cancer Informatics, Vol 2014, Iss Suppl. 4, Pp 65-72 (2014)
Externí odkaz:
https://doaj.org/article/a292244d0dbf4fef9ea5bd4c9a08b575
Autor:
Nibedita Chattopadhyay, Allison J Berger, Erik Koenig, Bret Bannerman, James Garnsey, Hugues Bernard, Paul Hales, Angel Maldonado Lopez, Yu Yang, Jill Donelan, Kristen Jordan, Stephen Tirrell, Bradley Stringer, Cindy Xia, Greg Hather, Katherine Galvin, Mark Manfredi, Nelson Rhodes, Ben Amidon
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Externí odkaz:
https://doaj.org/article/1d976cb67df14d88a310d90883ff9f3f
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bf51cd992431bfa10c2e6773dbd8053
https://doi.org/10.1158/1078-0432.c.6520107
https://doi.org/10.1158/1078-0432.c.6520107
Autor:
Siegfried Janz, Brian Van Ness, Joseph B. Bolen, Mark Manfredi, Erik Kupperman, Allison J. Berger, Vishala T. Neppalli, Mary Carsillo, Paul Hales, Ping Li, Olga Tayber, Zhi Li, Michael Pickard, Ray Liu, Matthew D. Silva, Ozlem Subakan, Daniel P. Bradley, Jennifer Terkelsen, Kristen Bano, Jill Donelan, Bret Bannerman, Michael Fitzgerald, Edmund C. Lee
PDF file - 108K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::24fd400a1ca08e8405e5d218dd1e0d4b
https://doi.org/10.1158/1078-0432.22444227.v1
https://doi.org/10.1158/1078-0432.22444227.v1
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 614K, Cellular effects of TAK-632, vemurafenib, and TAK-733 on MAPK signaling (S1); Model describing RAF paradoxical activation (S2); Effects of TAK-632 and vemurafenib on BRAF kinase activity (S3); Reversibility of TAK-632 and vemurafenib
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdcaf05c51ce47ecf2912f5b05346bc5
https://doi.org/10.1158/0008-5472.22398855.v1
https://doi.org/10.1158/0008-5472.22398855.v1
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 103K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3d6e57be0280b50c7eb627a772539273
https://doi.org/10.1158/0008-5472.22398852
https://doi.org/10.1158/0008-5472.22398852
Autor:
Sei Yoshida, Tomoyasu Ishikawa, Masanori Okaniwa, Katherine Galvin, Elizabeth Carideo, Jouhara Chouitar, Jill Donelan, Shuntarou Tsuchiya, Takeo Arita, Akito Nakamura
PDF file - 119K
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ed2773d2e203edffde7e16a28cb8d4c
https://doi.org/10.1158/0008-5472.22398858.v1
https://doi.org/10.1158/0008-5472.22398858.v1
Autor:
Katherine Galvin, Shuntarou Tsuchiya, Jouhara Chouitar, Sei Yoshida, Tomoyasu Ishikawa, Jill Donelan, Elizabeth Carideo, Masanori Okaniwa, Takeo Arita, Akito Nakamura
Publikováno v:
Cancer Research. 73:7043-7055
The mitogen-activated protein kinase (MAPK) pathway is particularly important for the survival and proliferation of melanoma cells. Somatic mutations in BRAF and NRAS are frequently observed in melanoma. Recently, the BRAF inhibitors vemurafenib and
Autor:
Jill Donelan, Stephen Tirrell, Erik Koenig, Bradley Stringer, Kristen Jordan, Cindy Q. Xia, Mark Manfredi, Allison Berger, Yu Yang, Angel Maldonado Lopez, James Garnsey, Nelson Rhodes, Katherine Galvin, Ben Amidon, Paul Hales, Nibedita Chattopadhyay, Hugues Bernard, Bret Bannerman, Greg Hather
Publikováno v:
PLoS ONE, Vol 10, Iss 12, p e0144825 (2015)
PLoS ONE
PLoS ONE
In non-clinical studies, the proteasome inhibitor ixazomib inhibits cell growth in a broad panel of solid tumor cell lines in vitro. In contrast, antitumor activity in xenograft tumors is model-dependent, with some solid tumors showing no response to
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort